Vaccine Types

Why This Matters

Vaccines represent one of immunology's greatest applications: the deliberate manipulation of adaptive immunity to prevent disease. You're being tested on more than just knowing vaccine names. Exams focus on how different vaccine platforms activate the immune system, why certain designs trigger stronger or longer-lasting responses, and which approaches work best for different patient populations. Understanding the mechanisms behind antigen presentation, T cell activation, humoral vs. cellular immunity, and immunological memory will help you predict how each vaccine type performs.

The diversity of vaccine platforms reflects the complexity of pathogens themselves. Some vaccines mimic natural infection closely; others deliver only the minimum antigenic information needed. Each design involves trade-offs between immunogenicity, safety, and practicality. Don't just memorize examples. Know what immunological principle each vaccine type demonstrates and why that matters for protection.

---

Whole-Pathogen Vaccines

These traditional approaches expose the immune system to complete pathogens, either weakened or killed. The more closely a vaccine mimics natural infection, the more robust and diverse the immune response, but with greater safety considerations.

Live Attenuated Vaccines

• Contain weakened pathogens that replicate without causing disease. This replication amplifies antigen load over time and activates pattern recognition receptors (PRRs) on innate immune cells, providing built-in adjuvant-like signals.
• Stimulate both humoral and cellular immunity. Because the attenuated pathogen replicates inside host cells, antigens are processed and presented via both MHC Class I (activating $CD8^+$ cytotoxic T cells) and MHC Class II (activating $CD4^+$ helper T cells). This is the closest immunological mimic to natural infection, often providing lifelong protection with fewer doses.
• Contraindicated in immunocompromised patients. There is a rare but real risk of reversion to virulence (the attenuated strain mutating back toward pathogenicity). In a patient with a weakened immune system, even a mildly virulent revertant can cause serious disease.

Examples: MMR (measles, mumps, rubella), oral polio (Sabin), varicella, yellow fever.

Inactivated (Killed) Vaccines

• Pathogens are chemically or heat-killed, eliminating all replication capacity and any risk of causing disease.
• Primarily stimulate humoral immunity. Without intracellular replication, antigens are mostly taken up by APCs and presented via MHC Class II. MHC Class I presentation is limited, so $CD8^+$ cytotoxic T cell responses are weak.
• Require multiple doses and adjuvants. Because there's no replication to amplify antigen exposure or trigger strong innate signals, boosters are essential for building and maintaining protective antibody titers.

Examples: Inactivated polio (Salk), influenza (injected), hepatitis A, rabies.

---

Component-Based Vaccines

Rather than using whole pathogens, these vaccines deliver specific antigenic pieces. This targeted approach minimizes side effects but often requires adjuvants to compensate for reduced immunogenicity.

Subunit Vaccines

• Contain purified proteins or polysaccharides from the pathogen surface. No genetic material or whole organisms are present.
• Highly targeted immune response with an excellent safety profile. Because you're delivering only a defined antigen, there's minimal reactogenicity, making these ideal for patients where adverse reactions are a concern.
• Require adjuvants to enhance immunogenicity. Purified antigens alone lack the PAMPs (pathogen-associated molecular patterns) that innate immune sensors recognize. Adjuvants (like aluminum salts) compensate by providing the "danger signals" that boost APC activation and co-stimulation.

Examples: Hepatitis B (recombinant HBsAg), HPV, acellular pertussis.

Toxoid Vaccines

• Contain chemically inactivated toxins (toxoids), training the immune system to neutralize the toxin rather than the pathogen itself. Formaldehyde treatment destroys toxicity while preserving the antigenic epitopes.
• Protect against toxin-mediated diseases like tetanus and diphtheria. The resulting antibodies (antitoxins) block toxin binding to host cell receptors, preventing disease even if the bacterium itself is present.
• Require periodic boosters. Antibody titers wane over time without the sustained stimulation that replicating antigens provide. This is why you get a Td/Tdap booster every 10 years.

Conjugate Vaccines

• Link poorly immunogenic polysaccharide antigens to immunogenic carrier proteins. This recruits T cell help for what would otherwise be a T-independent response.
• Critical for protecting young children. Infants and toddlers have immature marginal zone B cells and cannot mount effective T-independent responses to polysaccharide antigens alone. The protein carrier ensures $CD4^+$ T cell engagement.
• Convert T-independent to T-dependent responses. Here's why this matters: T-dependent activation enables class switching (from IgM to IgG), affinity maturation in germinal centers, and the formation of long-lived memory B cells. Pure polysaccharide vaccines produce only short-lived IgM responses with no memory.

Examples: Hib (Haemophilus influenzae type b), PCV13 (pneumococcal conjugate), meningococcal conjugate.

---

Genetic Vaccines

These modern platforms deliver genetic instructions rather than preformed antigens. Host cells produce the target protein endogenously, enabling MHC Class I presentation and robust cellular immunity.

mRNA Vaccines

• Deliver messenger RNA encoding pathogen proteins (typically encapsulated in lipid nanoparticles for delivery into cells). Host ribosomes translate the mRNA in the cytoplasm, and the resulting protein is processed through normal antigen presentation pathways.
• Stimulate strong humoral and cellular immunity. Because the protein is produced inside host cells, it enters the MHC Class I pathway (activating $CD8^+$ T cells). Secreted or released protein is also taken up by APCs for MHC Class II presentation (activating $CD4^+$ T cells and driving B cell responses).
• No risk of genomic integration or infection. mRNA never enters the nucleus and is degraded by normal cellular RNases within days. There is no reverse transcriptase to convert it to DNA.

Examples: Pfizer-BioNTech and Moderna COVID-19 vaccines.

DNA Vaccines

• Use plasmid DNA to encode pathogen antigens. The plasmid must enter the nucleus for transcription into mRNA, which is then translated in the cytoplasm.
• Largely experimental in humans. The nuclear entry requirement creates a major delivery bottleneck. Immunogenicity in human trials has generally been lower than in animal models, limiting clinical applications so far. (A few veterinary DNA vaccines are licensed.)
• Offer stability advantages. DNA is more thermostable than mRNA, potentially reducing or eliminating cold-chain requirements, which matters for global distribution.

Recombinant Vector Vaccines

• Use a harmless, often replication-deficient virus (the vector) to deliver pathogen genetic material. The vector infects host cells and expresses the target antigen from within.
• Induce both humoral and cellular immunity. The vector's own viral components activate innate immune pathways (acting as a built-in adjuvant), while the expressed target antigen drives adaptive responses through both MHC Class I and Class II.
• Pre-existing vector immunity can limit effectiveness. If a patient already has antibodies against a common vector like adenovirus serotype 5, those antibodies may neutralize the vaccine vector before it can infect cells and express the target antigen. This is why some platforms use rare human serotypes or non-human adenoviruses (e.g., chimpanzee adenovirus in the Oxford-AstraZeneca vaccine).

Examples: J&J/Janssen COVID-19 (Ad26 vector), Oxford-AstraZeneca COVID-19 (ChAdOx1 vector), Ebola vaccine (rVSV-ZEBOV).

---

Quick Reference Table

---

Self-Check Questions

1. Which vaccine types produce antigens endogenously within host cells, and why does this matter for the type of immunity generated?

2. A patient is immunocompromised following chemotherapy. Which vaccine platforms would be contraindicated, and what immunological principle explains this restriction?

3. Compare and contrast conjugate vaccines and standard subunit vaccines. What specific immunological problem do conjugate vaccines solve, and for which patient population is this most critical?

4. Explain why live attenuated vaccines typically require fewer doses than inactivated vaccines. What mechanisms account for this difference in immunogenicity?

5. Both mRNA and recombinant vector vaccines emerged as COVID-19 vaccine platforms. What advantage do they share over traditional approaches, and what is one key difference in how they deliver genetic material to host cells?